Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

First in-human trial of AMV564 for AML

Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA

First in-human trial of AMV564 for AML ( Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA )

SETBP1 induces transcription of developmental genes

Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy

SETBP1 induces transcription of developmental genes ( Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy )

Combination therapy for CLL in the CAPTIVATE trial

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Combination therapy for CLL in the CAPTIVATE trial ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia

Prof Philipp Staber - Medical University of Vienna, Vienna, Austria

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia ( Prof Philipp Staber - Medical University of Vienna, Vienna, Austria )

Isatuximab in combination to treat relapsed/refractory MM

Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma...

$Isatuximab in combination to treat relapsed/refractory MM ( Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation )$

Venetoclax in patients with previously treated WM

Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA

Venetoclax in patients with previously treated WM ( Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA )

Single cell profiling reveals key differences in architecture of stem and...

Dr Anindita Roy - University of Oxford, Oxford, UK

Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life ( Dr Anindita Roy - University of Oxford, Oxford, UK )

ICLL07 FILO study: Minimal residual disease still detectable after first line...

Prof Pierre Feugier - University of Lorraine, Nancy, France

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy ( Prof Pierre Feugier - University of Lorraine, Nancy, France )

Even late progressors with high risk factors in PRIMA prognostic index are more...

Prof Marek Trněný - Charles University, Prague, Czech Republic

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die ( Prof Marek Trněný - Charles University, Prague, Czech Republic )

Patient relevant outcomes and advocacy

Jan Geissler - CML Advocates Network, EuroBloodNET ePAG

Patient relevant outcomes and advocacy ( Jan Geissler - CML Advocates Network, EuroBloodNET ePAG )

The mutational landscape of AML

Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany

The mutational landscape of AML ( Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany )

Development of a risk stratifying prognostic index for ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Development of a risk stratifying prognostic index for ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

More from ecancer